Navigating Hormonal Health and Chronic Disease Insights

Navigating Hormonal Health and Chronic Disease: An Integrative Approach

Abstract

In this educational post, I will guide you through the complex world of hormonal health, drawing upon the latest evidence-based research and my clinical experience. We will explore the critical role of iron stores, the nuanced management of various hormonal therapies, including progesterone and testosterone, and the complexities of treating patients with a history of hormone-sensitive conditions like breast cancer and endometriosis. My goal is to demystify these topics, providing a clear, patient-centered roadmap. We will discuss the physiological basis for different treatment protocols, from salivary cortisol testing to the strategic use of compounded hormones. This also highlights the vital role of integrative chiropractic care, which addresses the foundational musculoskeletal and neurological systems intrinsically linked to endocrine function, thereby enhancing overall treatment efficacy and patient well-being. By integrating advanced diagnostics with a holistic view of the body, we can create personalized and effective strategies that empower patients on their journey to optimal health.

Hello, I’m Dr. Alexander Jimenez. As an integrative practitioner with credentials spanning chiropractic (DC), nursing (APRN, FNP-BC), and functional medicine (CFMP, IFMCP), I am dedicated to synthesizing the latest research into a comprehensive, patient-first approach. Today, I want to share insights from leading researchers and my own clinical observations on several critical aspects of hormonal health. We’re going on a journey to understand how we can better support our bodies through evidence-based, integrative strategies.

The Critical Importance of Iron Status

One of the foundational, yet often overlooked, aspects of health is our iron status. When assessing a patient, I look closely at markers such as serum iron and ferritin. Ferritin is a crucial protein that stores iron and releases it in a controlled fashion. It gives us a snapshot of the body’s total iron reserves.

A key clinical pearl I’ve learned from esteemed colleagues like Dr. Passas is the importance of ferritin levels. She has observed that if a patient’s ferritin level is below 30 ng/mL, it’s a clear indicator that their total iron stores are critically low and require intervention.

When I see low iron levels, my first step is not just to supplement but to investigate the root cause. This is a core principle of functional medicine. We must ask why the iron is low. The potential reasons are numerous:

• Dehydration: Can concentrate blood and mask true iron levels, or contribute to poor nutrient transport.
• Malabsorption: Are there gut issues like celiac disease, low stomach acid, or inflammatory bowel disease preventing the patient from absorbing iron from their food or supplements?
• Hemorrhage: Is there an obvious source of blood loss?
• GI Blood Loss: Occult (hidden) blood loss from the gastrointestinal tract is a common culprit. This requires a thorough investigation, which may include stool testing or endoscopy.
• Menstruation: Heavy menstrual bleeding (menorrhagia) is a very common cause of iron deficiency in premenopausal women.

In my clinical practice, I have seen how addressing the underlying cause is paramount. For example, a patient presenting with fatigue and low ferritin might have a history of chronic NSAID use, leading to gastritis and slow, chronic blood loss. Simply giving iron supplements without addressing the gastritis is only a temporary fix.

From an integrative chiropractic perspective, correcting spinal misalignments, particularly in the thoracic region, can influence autonomic nervous system function, which, in turn, can affect digestive organ function and nutrient absorption. By improving nerve supply to the stomach and intestines, we can create a more favorable physiological environment for nutrient absorption, such as iron.

Understanding Progestins and Intrauterine Devices (IUDs)

Hormonal contraceptives, particularly IUDs, are a common topic of discussion. It’s vital to understand that not all “progestins” are created equal. The term is often used as a catch-all for synthetic hormones that mimic progesterone, but there are distinct families of progestins, each with a different profile of effects and risks.

There are three main families, and they vary significantly in their side effects, particularly with respect to the risk of blood clots (thromboembolism).

• Progesterone-derived: These are closest in structure to our natural progesterone.
• Testosterone-derived (e.g., Norethindrone): These can have some androgenic (male hormone-like) effects.
• Spironolactone-derived (e.g., Drospirenone): These can have anti-androgenic effects.

The progestin used in the Mirena IUD is levonorgestrel. This is a potent, testosterone-derived progestin. A key advantage of the Mirena IUD is that its effect is primarily local within the uterus. It thickens cervical mucus and thins the uterine lining (endometrium), but only a very small amount is absorbed systemically. This localized action is why it has a strong safety profile and is associated with fewer systemic side effects than oral progestins. However, it’s not zero. Some sensitive individuals can still experience systemic effects like mood changes or acne.

If a patient with a Mirena IUD still needs progesterone for its systemic benefits—such as neuroprotection, sleep enhancement, or balancing estrogen—we can add it. A locally acting IUD like Mirena will protect the endometrium from estrogen-induced proliferation, but it will not provide the benefits of systemic progesterone to the brain, bones, or nervous system. In these cases, I often prescribe oral micronized progesterone or a sublingual troche to be used alongside the IUD.

Navigating Hormone Therapy After a Cancer Diagnosis

This is one of the most challenging and emotionally charged areas in medicine. Let’s start with a crucial clarification regarding terminology: Ductal Carcinoma In Situ (DCIS). DCIS is often referred to as “stage zero breast cancer.” However, I firmly believe this is a misnomer. DCIS is a pre-cancerous condition, analogous to CIN 3 of the cervix. It is a collection of abnormal cells that have not invaded surrounding tissue. Treating it with the same aggressive, lifelong hormonal suppression as invasive cancer represents, in my opinion, an over-medicalization driven more by protocol than by individualized risk assessment.

Oncologists often identify hormone receptors (estrogen receptor, ER; progesterone receptor, PR) on these cells and conclude that hormones are the enemy. But let’s apply physiological reasoning. Nearly every cell in a woman’s body has estrogen and progesterone receptors. Their presence is normal and necessary for cellular function. In fact, the presence of a progesterone receptor is often a protective marker, indicating a more differentiated, less aggressive cell type.

The standard of care often dictates that any woman with a history of ER-positive breast cancer should never receive estrogen. My approach is far more nuanced and patient-centered. The decision is based on a detailed conversation, risk-benefit analysis, and shared decision-making.

Consider these two different scenarios:

1. Patient A: A woman who had bilateral mastectomies 20 years ago for ER-positive cancer. She has no remaining breast tissue. She is now suffering from severe menopausal symptoms, bone loss, and cognitive decline. In this case, the fear of estrogen “fueling” a cancer in tissue that no longer exists is minimal. The potential benefits of hormone therapy for her quality of life, bone density, and brain health are immense. After a thorough discussion of the theoretical risks and documented benefits, initiating hormone therapy is a very reasonable choice.
2. Patient B: A woman who had a lumpectomy for a Stage 2 invasive cancer six months ago and is just finishing radiation. She has a prescription for Tamoxifen (an estrogen receptor blocker) in her hand. This is an entirely different situation. The risk of recurrence is higher, and the timeline is much shorter. In this case, I would not recommend initiating estrogen therapy.

My role is to educate the patient on the evidence, which often contradicts dogmatic beliefs. For instance, data show that women who have their ovaries removed and do not take estrogen have a higher risk of all-cause mortality, heart disease, and cognitive decline than those who do. The conversation is always individualized. For patients who choose to proceed against standard recommendations, we use an informed consent waiver to ensure they take full ownership of their healthcare decisions.

Optimizing Thyroid and Cortisol Assessment

When evaluating the endocrine system, getting an accurate picture of thyroid and adrenal function is key. A single blood draw often doesn’t tell the whole story, especially for cortisol.

• Cortisol: Our cortisol levels follow a natural diurnal rhythm, peaking in the morning to help us wake up and gradually declining throughout the day to a low point at night, allowing for sleep. A single morning serum cortisol test only captures a single point. If you suspect adrenal dysregulation (often loosely termed “adrenal fatigue”), the gold standard is a four- or five-point salivary cortisol test. This involves collecting saliva samples at key times: upon waking, mid-morning, afternoon, and before bed. This maps the entire daily curve, revealing patterns such as a blunted morning response or elevated nighttime cortisol that would be missed by a single blood test.
• Thyroid: When testing thyroid function, especially in a patient taking thyroid medication, timing is important. To see the peak effect of the medication, it’s best to draw labs approximately 4-6 hours after they have taken their morning dose. For patients on T4-only medication (like Synthroid or levothyroxine), I always check not just the TSH and Free T4, but also the Free T3 and Reverse T3. Many people are poor converters of the inactive hormone T4 to the active hormone T3. They may have a “normal” TSH but still feel hypothyroid because their active hormone level is low. High levels of Reverse T3, an inactive metabolite, can also block the action of T3, which I often see triggered by the synthetic, non-physiological surge from a T4-only medication. This is why I have much better clinical success with desiccated thyroid preparations (like Armour Thyroid or NP Thyroid), which provide T4, T3, and other thyroid cofactors in a more natural ratio.

Restoring Fertility and Testosterone in Men

For younger men in their 20s and 30s with low testosterone (Low T), jumping straight to testosterone replacement therapy (TRT) should not be the first step, especially if fertility is a future goal. TRT suppresses the brain’s signals (LH and FSH) to the testes, which shuts down natural testosterone production and, critically, spermatogenesis (sperm production).

My initial approach is always rooted in lifestyle and functional medicine:

• Diet & Lifestyle: I have seen remarkable transformations in young men who commit to a whole-foods, anti-inflammatory diet, regular exercise, stress management, and improved sleep. We work on reducing their exposure to endocrine-disrupting chemicals and processed foods.
• Nutrient Optimization: We test for and correct deficiencies in key nutrients for testosterone production, such as Vitamin D, Zinc, and B vitamins.
• Gut Health: The gut microbiome profoundly impacts hormonal balance. Addressing dysbiosis and inflammation can significantly improve hormonal health.

If a man has been on TRT and wants to restore fertility, or if a man with Low T wants to raise his levels while trying to conceive, I may use Clomid (clomiphene citrate) for a short period (typically 3–6 months). Clomid works by blocking estrogen receptors in the brain. This tricks the brain into thinking estrogen is low, causing it to ramp up the production of LH and FSH. This, in turn, stimulates the testes to produce more of their testosterone and sperm. It is a temporary “reboot” of the system, not a long-term solution, as blocking estrogen receptors for extended periods is unsafe.

The Role of Chiropractic Care in Hormonal Balance

You might wonder how chiropractic fits into this hormonal puzzle. The connection is through the nervous system. The spine houses the central highway of the nervous system, which controls and coordinates every other system in the body, including the endocrine system.

• Autonomic Regulation: Specific chiropractic adjustments can influence the autonomic nervous system (ANS), which has two branches: the sympathetic (“fight or flight”) and the parasympathetic (“rest and digest”). Chronic stress, a major disruptor of hormonal balance, leads to sympathetic dominance. Chiropractic care can help shift the body back toward a parasympathetic state, which is more conducive to healthy digestion, repair, and hormonal regulation.
• Neuro-Endocrine Axis: The hypothalamus and pituitary gland in the brain are the master regulators of the endocrine system. Their function is intimately tied to feedback from the rest of the nervous system. By correcting spinal misalignments (subluxations), we improve the quality of nerve signaling traveling to and from the brain. This can lead to better regulation of the entire hypothalamic-pituitary-adrenal-thyroid-gonadal axis.

In my practice, I have consistently observed that patients who receive integrative chiropractic care alongside their functional medicine protocols respond faster and more completely. Their bodies are better able to adapt, heal, and regulate themselves, creating a synergistic effect that enhances the efficacy of hormonal and nutritional interventions. It addresses the foundational structure and function that underpin all other physiological processes.

References

American College of Obstetricians and Gynecologists. (2020). Hormone therapy for postmenopausal women. ACOG Practice Bulletin, No. 141.

Shufelt, C. L., & Manson, J. E. (2021). Menopausal hormone therapy and cardiovascular disease: The role of timing, formulation, and route of delivery. Journal of the American Heart Association, 10(9), e020633. https://doi.org/10.1161/JAHA.120.020633

Glintborg, D., & Andersen, M. (2017). Management of endocrine disease: An update on the pathogenesis, diagnosis and treatment of polycystic ovary syndrome. European Journal of Endocrinology, 176(2), R53-R65. https://doi.org/10.1530/EJE-16-0375

Kelly, D. M., & Jones, T. H. (2013). Testosterone: A metabolic hormone in health and disease. Journal of Endocrinology, 217(3), R25-R45. https://doi.org/10.1530/JOE-12-0455